Table of frequent aberrant markers in AML: Difference between revisions
From haematologyetc.co.uk
(Created page with "It is well recognised that marker expression in acute myeloid leukaemia may frequently include the expression of immunological markers not typically associated with myeloid lineage. Broadly, the abberant expression may include: Markers of primitive phenotype that are more frequently associated with lymphoid disorders, most frequently, CD7 43% BCRABL TdT 7% Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly mon...") |
No edit summary |
||
| (5 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
---- | |||
<div style="width: 200px"> | |||
{| class="wikitable" style="border-left:solid 5px green;border-right:solid 5px green;border-top:solid 5px black;border-bottom:solid 5px black; font-size:90%; color:navy" | |||
| colspan="1"''|[[The flow cytometric diagnosis of AML|Return to previous page]]'' | |||
|} | |||
</div> | |||
---- | |||
<div style="width: 100%"> | |||
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black" | |||
|colspan="1" style = "font-size:90%; color:black; background: #bcd4e6"|'''What s the importance of abberent marker expression?''' | |||
|} | |||
</div> | |||
The key point is that AML will frequently express immunological markers not typically associated with myeloid lineage. This is aknowledged in diagnostic criteria and providing diagnostic criteria are applied they do not require a change in diagnosis.</br>The most frequent "abberencies" observed in AML are</br> | |||
</br>(1) The expression of CD7 by nearly half of cases</br>(2) The expression of CD19 (often associated with particular AML subtypes) | |||
----- | |||
<div style="width: 100%"> | |||
{| class="wikitable" style="border-style: solid; border-width: 5px; color:black" | |||
|colspan="1" style = "font-size:90%; color:black; background: #bcd4e6"|'''Do abberent markers have patterns?''' | |||
|} | |||
</div> | |||
Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly monocytic lineage | Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly monocytic lineage | ||
CD2 CD4, 36 38 MONOCYTIC 5% | CD2 CD4, 36 38 MONOCYTIC 5% | ||
Frequent abberant markers in AML that are often associated with genetic/cytogenetic subtype: | Frequent abberant markers in AML that are often associated with genetic/cytogenetic subtype: | ||
| Line 13: | Line 29: | ||
CD56 CBF RUNX1 | CD56 CBF RUNX1 | ||
NPM1 OFTEN LACK CD34 | NPM1 OFTEN LACK CD34 | ||
---- | |||
Latest revision as of 17:26, 12 January 2024
| What s the importance of abberent marker expression? |
The key point is that AML will frequently express immunological markers not typically associated with myeloid lineage. This is aknowledged in diagnostic criteria and providing diagnostic criteria are applied they do not require a change in diagnosis.
The most frequent "abberencies" observed in AML are
(1) The expression of CD7 by nearly half of cases
(2) The expression of CD19 (often associated with particular AML subtypes)
| Do abberent markers have patterns? |
Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly monocytic lineage CD2 CD4, 36 38 MONOCYTIC 5%
Frequent abberant markers in AML that are often associated with genetic/cytogenetic subtype: CD19 30% CBF RUNX1, BCRABL CD56 CBF RUNX1 NPM1 OFTEN LACK CD34